SHELTER PHARMA LIMITED

Shelter Pharma Limited (SHELTER) is an Indian pharmaceutical company with over six decades of experience in natural healthcare and wellness, operating in both human and veterinary segments. The company primarily focuses on herbal formulations, combining traditional Ayurveda and Unani healthcare systems with modern research and technology. It offers a portfolio of over 300 formulations, including tablets, capsules, powders, syrups, oils, and ointments, catering to a wide spectrum of health needs. While maintaining a strong base in Gujarat, Shelter Pharma is expanding its market presence across India and in international markets.

Key facts (FY2025-26):

• Revenue from operations for FY2026 stood at INR 73.13 crores, marking a 44.36% year-on-year growth.
• Revenue mix is approximately 55% from the veterinary segment and 45% from human healthcare.
• The company boasts a diversified portfolio of over 300 formulations, with approximately 200 in human healthcare and almost 100 in animal healthcare.
• Manufacturing is carried out in a GMP, HACCP, ISO 9001, and ISO 22000 certified unit in Himmatnagar, Gujarat, supported by an FDA-approved R&D facility.
• Shelter Pharma has a distribution network across more than 15 states in India and exports to over 10 countries, including UAE, Kuwait, Iraq, Qatar, Nepal, Bangladesh, Mauritius, Yemen, and Sudan.
• The company's promoters are Mr. Mustaqim Nisarahmed Sabugar (Chairman & Managing Director) and Mr. Shakil Nisarahmed Sabugar (Whole Time Director).

Recent developments (FY2025-26):

• The company reported robust financial growth, with Profit After Tax (PAT) increasing by 24.73% to INR 9.03 crores.
• A new range of high-value Nutraceutical and herbal healthcare products is being prepared for launch, leveraging advanced technology.
• Shelter Pharma is pursuing aggressive market expansion, targeting annual revenues of approximately INR 200 crores by FY2030 through capacity expansion and global market penetration.
• Land near Ahmedabad has been acquired for a second manufacturing facility (costing ~INR 2.5 crores), primarily funded through internal accruals.
• Export revenues increased by 164% in FY26, and the company is in discussions to deepen its presence in Africa, Qatar, and Yemen.

Key risks flagged by management (FY2025-26):

• Regulatory and Compliance Risk: The pharmaceutical sector is subject to stringent regulatory standards, where non-compliance can impact operations and reputation.
• Input Cost and Supply Chain Risk: Volatility in key starting material (KSM)/API prices and potential supply disruptions may affect margins and production.
• Competitive and Pricing Pressure: The branded generics market is highly competitive, leading to pricing pressures that could impact profitability and market share.
• Working Capital Intensity: Managing receivables, inventory, and cash flows effectively is crucial for sustaining growth.

Pros (FY2025-26):

• Strong revenue and profit growth in FY26, indicating effective strategic initiatives and market positioning.
• Diversified product portfolio across human and veterinary healthcare, reducing reliance on a single segment.
• Low-debt company with a commitment to funding growth through internal accruals, suggesting financial prudence.

Cons (FY2025-26):

• EBITDA margin declined from 19.6% in FY25 to 17.4% in FY26, attributed to expansion mode.
• Cash flow from operating activities was negative INR 12.48 crores, and the working capital cycle remained high at 234 days due to market expansion efforts and extended credit periods.
• The Secretarial Auditor noted non-compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding material related party transactions during the year.